Inactive Instrument

Press Releases Proteo, Inc.

Equities

PTEO

US74369R4074

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

PROTEO INC : Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	20-07-20	AQ
PROTEO INC : Submission of Matters to a Vote of Security Holders (form 8-K)	20-07-10	AQ
PROTEO : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	20-06-05	AQ
PROTEO INC : Other Events (form 8-K)	20-05-12	AQ
PROTEO : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	20-05-07	AQ
PROTEO INC : Other Events (form 8-K)	20-03-30	AQ
PROTEO INC : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)	20-03-03	AQ
Proteo Inc : Patient recruitment and treatment in Elafin CABG Phase II clinical trial completed	13-11-08	PU
PROTEO INC : Proteo, Inc. / Proteo Biotech AG: EMPIRE-Study recruits first coronary bypass patients	11-08-16	PU
PROTEO INC : Proteo, Inc./ Proteo Biotech AG: Proteo's Elafin Will Be Tested at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)	10-06-18	BU
PROTEO : Proteo, Inc./Proteo Biotech AG: Clinical Study in Harvard Reveals Elafin Deficiency in Acute Respiratory Distress Syndrome (ARDS)	09-02-17	BU
PROTEO : Inc./Proteo Biotech AG - Minapharm/Rhein Minapharm Biogenetics SAE: Approval for a Phase II Clinical Trial with Elafin in Kidney Transplantation	08-12-10	BU
PROTEO : Proteo, Inc./Proteo Biotech AG: Start of the Phase II clinical trial with Elafin	08-11-17	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer